What are the recommended dosing regimens for hepatitis C virus infection, including pan‑genotypic (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) and genotype‑specific (sofosbuvir/ledipasvir) therapies, and how should ribavirin be dosed and adjusted for patient weight and renal impairment?

Hepatitis C Dosing Recommendations

For pan-genotypic treatment of chronic HCV infection, use glecaprevir/pibrentasvir (300mg/120mg) as three tablets once daily with food for 8 weeks in treatment-naïve patients without cirrhosis, or sofosbuvir/velpatasvir (400mg/100mg) as one tablet once daily for 12 weeks regardless of cirrhosis status. 1, 2, 3

Pan-Genotypic Regimens

Glecaprevir/Pibrentasvir (GLE/PIB)

Adult Dosing:

• Standard dose: 300mg glecaprevir + 120mg pibrentasvir (three 100mg/40mg tablets) once daily with food 2

Treatment Duration by Patient Category:

• Genotypes 1,2,4,5,6:

  • Treatment-naïve without cirrhosis: 8 weeks 1, 2
  • Treatment-naïve with compensated cirrhosis: 8 weeks 1, 2
  • Treatment-experienced without cirrhosis: 8 weeks (if PRS-experienced); 12 weeks (if NS3/4A PI-experienced) 2
  • Treatment-experienced with compensated cirrhosis: 12 weeks 1, 2

• Genotype 3:

  • Treatment-naïve without cirrhosis: 8 weeks 1, 2
  • Treatment-naïve with compensated cirrhosis: 12 weeks (can consider 8 weeks but less data) 1, 2
  • Treatment-experienced without cirrhosis: 12 weeks 1, 2
  • Treatment-experienced with compensated cirrhosis: 16 weeks 1, 2

• Genotype 1 NS5A inhibitor-experienced: 16 weeks regardless of cirrhosis 2

Pediatric Dosing (≥3 years):

• Weight-based dosing using tablets or oral pellets 2
• Patients ≥45 kg or ≥12 years: adult dosing (three tablets daily) 2
• Patients <45 kg and 3-11 years: refer to weight-based tables in prescribing information 2

Sofosbuvir/Velpatasvir (SOF/VEL)

Adult Dosing:

• Standard dose: 400mg sofosbuvir + 100mg velpatasvir (one tablet) once daily with or without food 3

Treatment Duration:

• All genotypes (1-6), treatment-naïve or treatment-experienced, without cirrhosis or with compensated cirrhosis: 12 weeks 1, 3

Special Populations:

• Genotype 3 with compensated cirrhosis (treatment-naïve or experienced): Add weight-based ribavirin (1000mg if <75kg or 1200mg if ≥75kg) for 12 weeks 1
• Decompensated cirrhosis (Child-Pugh B or C): Add ribavirin for 12 weeks 3

Pediatric Dosing (≥3 years):

• Weight-based dosing using tablets or oral pellets 3
• Children <6 years: administer oral pellets with food 3

Genotype-Specific Therapy

Sofosbuvir/Ledipasvir (SOF/LDV)

Indications: Genotypes 1,4,5, or 6 4

Pediatric Dosing (≥3 years):

• Weight-based dosing per prescribing information 4

Treatment Duration:

• Treatment-naïve, genotypes 1/4/5/6, without cirrhosis or with compensated cirrhosis: 12 weeks 4
• Interferon-experienced, genotypes 1/4:
  • Without cirrhosis: 12 weeks 4
  • With compensated cirrhosis: 24 weeks 4

Ribavirin Dosing and Adjustments

Weight-Based Dosing

Standard weight-based ribavirin:

• <75 kg: 1000 mg daily (500mg twice daily) 1
• ≥75 kg: 1200 mg daily (600mg twice daily) 1

Renal Impairment Adjustments

Critical caveat: Ribavirin is renally cleared and requires dose adjustment in renal impairment. However, the evidence provided does not specify exact dose reductions for different levels of renal dysfunction. In clinical practice:

• CrCl >50 mL/min: Standard weight-based dosing
• CrCl 30-50 mL/min: Consider dose reduction and close monitoring
• CrCl <30 mL/min or hemodialysis: Ribavirin use is generally not recommended due to significant accumulation risk

Important: Sofosbuvir-containing regimens (SOF/VEL, SOF/LDV) can be used in patients with any degree of renal impairment, including end-stage renal disease on dialysis, without dose adjustment 2, 3. However, when ribavirin is added, renal function becomes the limiting factor.

Key Clinical Considerations

Drug Interactions to Avoid

• Do not coadminister with carbamazepine, efavirenz-containing regimens, or St. John's wort—these significantly decrease DAA concentrations 4, 2, 3
• GLE/PIB: Contraindicated with atazanavir and rifampin 2

Contraindications

• GLE/PIB: Contraindicated in moderate-to-severe hepatic impairment (Child-Pugh B or C) or any history of hepatic decompensation 2
• SOF/VEL + ribavirin: Contraindicated when ribavirin is contraindicated (pregnancy, severe cardiac disease, hemoglobinopathies) 3

Pre-Treatment Testing

• Mandatory HBV screening: Test all patients for HBsAg and anti-HBc before initiating DAA therapy due to risk of HBV reactivation 4, 2, 3

Monitoring During Treatment

• Patients with diabetes: Monitor glucose for hypoglycemia during and after treatment 4
• Patients on warfarin: Monitor INR closely as HCV clearance may alter dose-response 4
• Ribavirin recipients: Monitor hemoglobin for anemia 3

Treatment Selection Algorithm

For most patients (genotypes 1,2,4,5,6):

1. First choice: GLE/PIB for 8 weeks (shorter duration, higher pill burden) OR SOF/VEL for 12 weeks (longer duration, single tablet)
2. Consider GLE/PIB if shorter treatment preferred and no contraindications
3. Consider SOF/VEL if renal impairment present or single-tablet regimen preferred

For genotype 3 with compensated cirrhosis:

1. Treatment-naïve: SOF/VEL + ribavirin for 12 weeks (if Y93H RAS present or unknown) OR GLE/PIB for 12 weeks 1
2. Treatment-experienced: SOF/VEL + ribavirin for 12 weeks OR GLE/PIB for 16 weeks 1

For DAA-experienced patients:

• Genotype 1 NS5A inhibitor failures: GLE/PIB for 16 weeks 2
• Complex failures: Consider SOF/VEL/voxilaprevir (triple therapy) 1

The choice between GLE/PIB and SOF/VEL is clinically equivalent with SVR rates exceeding 95% across all genotypes 5, 6, 7, 8. The decision should be based on treatment duration preference, pill burden tolerance, drug interactions, renal function, and cirrhosis status rather than efficacy differences.